Part 2: Immunotherapies—A New Tool To Treat Methamphetamine Addiction? | National Institute on Drug Abuse (NIDA)
Feb 6, 2020 | Anti-METH antibody, IXT-m200
Recent Posts
- InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Use Disorder
- InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose
- InterveXion Announces Positive Data in Phase 2 Study of IXT-m200 in Participants with Methamphetamine Use Disorder
- InterveXion Therapeutics Awarded Federal Grant to Fund Phase 2 Study for Methamphetamine Overdose
- InterveXion Therapeutics Awarded Federal Grant to Fund Ongoing Development Program for IXT-m200 for Methamphetamine Use Disorder
Archives
- October 2021
- September 2021
- April 2021
- October 2020
- May 2020
- February 2020
- January 2020
- December 2019
- November 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- February 2019
- January 2019
- December 2018
- November 2018
- May 2018
- January 2018
- October 2017
- June 2017
- January 2016
- January 2015
- November 2014
- February 2014
- August 2013
- July 2013
- December 2012
- November 2012
- May 2012
- April 2012
- July 2011
- April 2011
- October 2009
- September 2009
- March 2005
- January 2005
Recent Comments